SAN JOSE, CA, January 10, 2019 – MGI, a subsidiary of global genomics leader BGI Group, announced WeGene as its first early access customer for the new ultra high-throughput sequencer, MGISEQ-T7.
MGI J.P. Morgan Healthcare Conference Highlights
1Interview | Brock Peters: Working Hard to Enable "Perfect Genome" Sequencing2MGI's "life science super computer" DNBSEQ-T7 officially delivered to business partners3New Emergency Detection Laboratory Run by BGI Starts Trial Operation in Wuhan, Designed to Test 10,000 Samples Daily4BGI Group Supports France to Secure Equipment for Two Million COVID-19 Tests5Sinai Health Receives Key COVID-19 Testing Equipment Honouring Internationally Renowned Canadian Physician Dr. Norman Bethune6BGI Partners with Minderoo to Launch Huo-Yan Laboratory Solution to Expedite Australia-wide COVID-19 Testing
MGI Wins Company Innovation of the Year at 2022 Globee® Awards for Advanced COVID-19 Response Efforts
MGI Announces Commercial Availability of DNBSEQ™ Sequencers* in the United States
MGI turns a new page in the human genome era with ultra-high throughout DNBSEQ-T7 sequencer*